Hanyu Medical closes RMB500m Series D

2020-08-15
|
Isiah Liu

Hanyu Medical closes RMB500m Series D

Hanyu Medical, a high-end cardiac device company, has closed a 500 million yuan Series D round of financing jointly led by Highlight Capital, CPE, Yingke PE.


The round also saw participation from Alan AMC, Everest Capital, Medfine Capital, Orient Securities Capital, TF Capital and Spring Fund.


The funds raised will be used to drive the launch of the company's product Valve Clamp, as well as the continued development of new products.


Founded in December 2016, Hanyu Medical is one of the first companies in China to carry out research, development, production and sales of heart valve interventional medical devices. Currently, the company's core product is Valve Clamp, a mitral valve interventional device for minimally invasive interventional treatment of mitral valve regurgitation disease.


Valve Clamp has full proprietary patent rightsin China and has applied for international PCT patents. In addition, Valve Clamp has completed 12 exploratory human clinical trials in October 2018, with a 100% success rate and 100% efficacy rate with no serious complications.


RELATED ARTICLES

Xbed Xi Hotel receives RMB100 million in financing
2020-11-18
|
Tourism , PEVC

Memoray completes tens of millions of yuan in Series B financing
2020-11-18
|
PEVC , Medical care

JD Health and AstraZeneca start strategic cooperation
2020-11-18
|
Medical care , Pharmaceutical

Sier Education closes multi-mln-dollar Pre-A led by Qiming Venture Partners
2020-10-26
|
Education , PEVC

Eugenlight Technologies closes Series A of RMB tens of millions
2020-09-13
|
PEVC , Semiconductor , Electroinic

Zion Pharma closes USD20m Series A+
2020-08-14
|
Medical care , PEVC , Pharmaceutical

Predicine closes RMB100m Series B1 round of strategic financing
2020-08-02
|
Medicine , PEVC

Cipher Gene secures multimillion-yuan Pre-B financing round
2020-07-23
|
PEVC , Medical care , Genetic

Denovo Biopharma nets nearly RMB600m in Series C round
2020-06-30
|
Pharmaceutical , PEVC

Lupeng Pharmaceutical closes RMB170m Series A+ round led by Lilly Asia Ventures
2020-06-25
|
Pharmaceutical , PEVC
China SDG